Achieving Drug Formulation Precision through Drug Absorption Models

A prevailing productivity crisis casts a shadow over drug development within the pharmaceutical industry. As costs soar and drug approvals dwindle, research-based companies face a formidable challenge—addressing poorly soluble drug candidates. This article delves into the multifaceted landscape of drug development, where an early emphasis on Absorption, Distribution, Metabolism, and Excretion (ADME) profiling becomes imperative for overcoming the biopharmaceutical hurdle.

The Evolution of ADME Models

The trajectory of pharmaceutical progress commences with fundamental principles such as the Lipinski rules and quantitative structure bioavailability relationships (QSBR), instrumental in foreseeing obstacles related to drug absorption. These foundational concepts set the stage for a transformative shift marked by the introduction of absorption potential and maximal absorbable dose, ushering in a new era in drug development. The evolution gains momentum with the advent of physiologically-based models, including compartmental absorption and transit models (CAT) and the advanced compartmental absorption transit model (ACAT). These models, encapsulating intricate physiological processes, redefine the landscape of drug absorption modeling, finding practical application in commercial software like GastroPlus™. The convergence of computational methods and in vitro experiments underscores a paradigmatic leap, exemplified by the dynamic capabilities of GastroPlus™, showcasing the industry’s commitment to advancing precision in drug development.

Clinical Formulation: From Early Phases to Clinical Realms

The exploration of drug development leads to a critical examination of clinical formulation strategy, where physiologically-based pharmacokinetic models (PBPK) play a pivotal role. These models, serving as essential instruments, provide a sophisticated understanding of pharmacokinetics in human subjects. The incorporation of parameters intricately connected to both the compound and its formulation marks a transformative phase in drug development. These models not only anticipate but also effectively navigate the complex landscape of biopharmaceutical challenges, beginning in the early stages of development. This proactive approach proves instrumental in streamlining processes, ultimately fostering cost savings in the drug development pipeline.

Modeling Factor Interactions for Informed Formulation Development

As the drug development journey progresses into human trials, absorption models reach new levels of complexity. Models like the advanced compartmental and transit model proposed for Talinolol exemplify the heightened refinement achieved through the incorporation of human exposure data. The significance of these advanced models becomes evident as they provide a clearer understanding of the intricacies involved in formulation development. This clarity enables targeted interventions and a rational approach to enhance bioavailability, reflecting a more informed and efficient trajectory in drug development.

Physiologically-Based Modeling in the Clinical Landscape

Physiologically-based modeling’s journey doesn’t cease with predictions; it catalyzes a feedback loop that refines in vitro testing conditions based on clinical data. This iterative process, exemplified in studies involving BCS class 2 drug glyburide, underscores the potential for these models as surrogates for bioequivalence studies. The article concludes with a visionary exploration of drug absorption design spaces (DADS), offering a tantalizing glimpse into a future where clinical bioavailability testing may be optimized or even omitted.

Refining the Clinical Landscape’s Future

This comprehensive exploration unravels the synergy of physiologically-based models and formulation development, promising transformative advancements in drug discovery. From early-phase anticipation to late-stage refinement, these models redefine the narrative of pharmaceutical innovation, ushering in an era where precision, cost-effectiveness, and a profound understanding of drug absorption converge to illuminate the path forward in drug development.

Study DOI: 10.1208/s12248-008-9054-3

Engr. Dex Marco Tiu Guibelondo, B.Sc. Pharm, R.Ph., B.Sc. CpE

Editor-in-Chief, PharmaFEATURES